Brief: Vaxxinity Announces First Participant Dosed In Phase 3 Study Of Next-Generation Covid-19 Vaccine Booster
28/03/2022 13:58
March 28 (Reuters) - Vaxxinity Inc VAXX.O :
* VAXXINITY ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 3
STUDY OF
NEXT-GENERATION COVID-19 VACCINE BOOSTER
* VAXXINITY INC - EXPECTS TO DELIVER A TOPLINE READOUT OF
UB-612
STUDY IN SECOND HALF OF 2022
Source text for Eikon: ID:nGNX5q3XkS
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview